Related Experiment Video
Updated: Sep 25, 2026
Surgical Techniques to Optimize Ovarian Reserve during Laparoscopic Cystectomy for Ovarian Endometrioma
Published on: January 22, 2022
Gonadotropin-releasing hormone agonist treatment before abdominal myomectomy: a controlled trial
Paolo Vercellini1, Laura Trespìdi, Barbara Zaina
1Clinica Ostetrica e Ginecologica I, Istituto Luigi Mangiagalli, University of Milan, Milan, Italy. paolo.vercellini.@unimi.it
Objective:
To ascertain whether adjuvant gonadotropin-releasing hormone (GnRH) agonist therapy decreases blood loss during abdominal myomectomy.
Design:
Randomized controlled trial.
Setting:
Academic reproductive surgery center.
Patient(S):
One hundred premenopausal women requiring first-line conservative surgery for symptomatic intramural or subserous fibroids.
Intervention(S):
Eight weeks of treatment with depot triptorelin before myomectomy or immediate surgery.
Main Outcome Measures:
Intraoperative blood loss, operating time, degree of difficulty of the procedure, and short-term rate of fibroid recurrence.
Result(S):
Mean (+/-SD) intraoperative blood loss was 265 +/- 181 mL in triptorelin recipients and 296 +/- 204 in patients who had immediate surgery (mean difference, -31 mL [95% CI, -108 to 46 mL]). No significant differences were observed in blood loss according to uterine volume, number of fibroids removed, or total length of myometrial incisions. Most procedures in either group were of routine difficulty. On ultrasonography 6 months after myomectomy, four women in the GnRH agonist group and one in the immediate surgery group had tumor recurrence.
Conclusion(S):
Treatment with a GnRH agonist before abdominal myomectomy has no significant effect on intraoperative blood loss. Thus, systematic use of medical therapy before abdominal myomectomy does not seem to be justified.
